Consistent with our results, in a randomized, double-blinded, placebo-controlled crossover trial in anti-GAD65-Ab-positive SPS patients, IVIG resulted in significant improvements in objective stiffness parameters and activities of daily living [44], and corticosteroids or other therapies may be very disappointing [45]. The gene discussed is GAD2; the disease is stiff-person syndrome.